IRIS
LAMBERTINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.089
Totale 15.089
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.089
Totale 15.089
Salva come PNG Salva come JPEG
Città #
Genova 9.523
Genoa 2.111
Vado Ligure 1.817
Rapallo 1.564
Bordighera 74
Totale 15.089
Salva come PNG Salva come JPEG
Nome #
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 152
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) 147
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 145
Cancer and fertility preservation: international recommendations from an expert meeting 145
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 141
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 139
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 130
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 128
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 124
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 123
Management of young women with early breast cancer 123
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open-Cancer Horizons" Series 122
Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences 120
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 119
Fertility, sexuality and cancer in young adult women 119
Reply to the letter "Safety of fertility preservation in women with breast cancer" 119
News on the medical treatment of young women with early-stage HER2-negative breast cancer 117
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 117
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 117
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 116
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 116
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 116
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 115
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 115
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 113
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 112
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 111
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 110
Treatment with aromatase inhibitors and markers of cardiovascular disease 109
Adherence to guidelines in requesting oncotype DX in a publicly funded health care system 109
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials 109
Letrozole withdrawal response in locally advanced breast cancer 108
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 107
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 105
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 105
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 104
Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients 104
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 103
Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma 103
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects 103
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 102
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 101
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives 101
Reply to the letter “Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association” 101
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 100
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 100
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting 99
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 98
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 98
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 97
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 96
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 95
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer 94
Adjuvant trastuzumab: a 10-year overview of its benefit 93
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 93
Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations 93
Targeted agents for cancer treatment during pregnancy 92
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients 92
Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape 92
Oncofertility counselling in premenopausal women with HER2-positive breast cancer 92
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer 92
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 92
Pregnancies in young women with diagnosis and treatment of HER2-positive breast cancer 91
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial 91
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors 90
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? 90
Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer 89
Follow-up strategies for women treated for early breast cancer 89
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients 89
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 89
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 88
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? 88
Breast cancer treatment-induced cardiotoxicity 88
Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies 87
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer 87
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: A NeoALTTO sub-study (BIG 1-06) 87
ESMO Leaders Generation Programme: an alumni insight 86
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy 86
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 85
Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients 84
Stevens-johnson syndrome after treatment with bendamustine 83
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials 83
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials 83
Long-term safety of pregnancy following breast cancer according to estrogen receptor status 82
Twenty years of anti-HER2 therapy-associated cardiotoxicity 81
What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab? 80
Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application 80
Implementing the hub and spoke model for the oncofertility units 79
How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer? 78
Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer 78
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 78
Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy 77
Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy? 77
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 77
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 77
Radiation therapy for young women with early breast cancer: Current state of the art 76
null 76
Emerging treatments for HER2-positive early-stage breast cancer: Focus on neratinib 76
Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: A view of the nation's young oncologists 76
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 75
Totale 10.009
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.727
article - articoli 69.727
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.789 0 0 0 0 0 0 788 458 482 564 385 112
2020/20212.215 117 151 274 293 148 132 203 194 139 247 140 177
2021/20222.453 166 82 108 237 58 230 82 523 278 259 98 332
2022/20232.027 265 194 38 162 269 260 53 186 376 16 186 22
2023/20241.623 53 153 38 198 111 143 93 112 87 113 135 387
2024/20252.147 141 376 97 278 671 541 43 0 0 0 0 0
Totale 15.920